Filing Flows › Supernus Pharmaceuticals (SUPN) › Guidance & outlook
Supernus Pharmaceuticals (SUPN) guidance and outlook
Supernus Pharmaceuticals (SUPN) reaffirmed its guidance on Oct 29, 2026: Revenue $1.3B–$1.4B for FY2026.
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $1.3B–$1.4B | reaffirmed |
From the earnings release filed Oct 29, 2026 (8-K on EDGAR).
Supernus Pharmaceuticals' latest quarter
Supernus Pharmaceuticals, Q3 2026: revenue $227M (+18% year over year), operating margin 9.3%, net earnings $20.9M, operating cash flow $6.6M. The chart follows the revenue to costs, profit and cash.
Questions
Did Supernus Pharmaceuticals raise or lower its guidance?
Supernus Pharmaceuticals (SUPN) reaffirmed its guidance on Oct 29, 2026: Revenue $1.3B–$1.4B for FY2026.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.